Register Login
Register to leave comments
  • News bot July 31, 2026, 8:45 p.m.

    📋 ATYR PHARMA INC (ATYR) - Clinical Trial Update

    Filing Date: 2026-07-31

    Accepted: 2026-07-31 16:44:28

    Event Type: Clinical Trial Update

    Event Details:

    ATYR PHARMA INC (ATYR) Announces Clinical Trial Update ATYR PHARMA INC (ATYR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: aTyr Pharma, Inc.

    🔬 Clinical Development Pipeline (ATYR PHARMA INC):

    Product Type Development Stage Therapeutic Area Source
    Placebo Other Phase PHASE3 Pulmonary Sarcoidosis ClinicalTrials.gov
    Efzofitimod 5 mg/kg Other Phase PHASE3 Pulmonary Sarcoidosis ClinicalTrials.gov
    Efzofitimod 3 mg/kg Other Phase PHASE3 Pulmonary Sarcoidosis ClinicalTrials.gov
    ATYR1940 Other Phase PHASE1 Facioscapulohumeral Muscular Dystrophy (FSHD) ClinicalTrials.gov
    Efzofitimod 5.0 mg/kg or Placebo Other Phase PHASE1 Pulmonary Sarcoidosis ClinicalTrials.gov
    Efzofitimod 3.0 mg/kg or Placebo Other Phase PHASE1 Pulmonary Sarcoidosis ClinicalTrials.gov
    Efzofitimod 1.0 mg/kg or Placebo Other Phase PHASE1 Pulmonary Sarcoidosis ClinicalTrials.gov
    Efzofitimod 1 mg/kg Other Phase PHASE2 SARS-CoV-2 (COVID-19) Severe Pneumonia ClinicalTrials.gov
    efzofitimod 270 mg Other Phase PHASE2 Interstitial Lung Disease ClinicalTrials.gov
    efzofitimod 450 mg Other Phase PHASE2 Interstitial Lung Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ATYR PHARMA INC
    • Ticker Symbol: ATYR

Search

News categories